Mar 04, 2020 / 04:20PM GMT
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Representing the company is Mike Severino, Vice Chairman and President; and Rob Michael, who is Executive Vice President and Chief Financial Officer.
Before we get into Q&A, I'd just like to say that when Cowen looks at AbbVie, we see a company that is delivering on its new product portfolio that is prepared for the HUMIRA patent expiration that has executed brilliantly since its public inception 6, 7 years ago, never having missed an earnings number, offers a 5.5% dividend yield, and sells at 8x 2020 numbers. That seems like a buy to us. That seems like a must-own stock.
Questions and Answers:
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystSo Mike, with that, the topic, of course, on everyone's mind right now is the Allergan transaction, and the company is saying you'll close in Q1. I mean Q1 is only a few more days to go. So can you talk about the latest relative to the transaction and
Trustpilot
